

Lurbinectedin (Zepzelca®)

Place of Service
Office Administration
Infusion Center Administration
Home Infusion Administration
Outpatient Facility Administration

HCPCS: J9223 per 0.1 mg

Condition listed in policy (see criteria for details)

- [Small cell lung cancer](#)

AHFS therapeutic class: Antineoplastic agent

Mechanism of action: Alkylating drug

(1) Special Instructions and pertinent Information

Covered under the medical benefit, please submit clinical information for prior authorization review via fax.

(2) Prior Authorization/Medical Review is required for the following condition(s)

All requests lurbinectedin (Zepzelca®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

Small cell lung cancer

1. Being used as subsequent treatment (second-line and beyond), **AND**
2. Being used as a single agent

Covered Dose:

Up to 3.2 mg/m² IV every 21 days

Coverage Period

Indefinite

ICD-10:

C7A.1, C33, C34.00-C34.02, C34.10-C34.12, C34.2, C34.30-C34.32, C34.80-C34.82, C34.90-C34.92, C78.00-C78.02, C79.31, C79.51, C79.52, Z85.118

(3) The following condition(s) DO NOT require Prior Authorization/Preservice

All requests for lurbinectedin (Zepzelca®) must be sent for clinical review and receive authorization prior to drug administration or claim payment.

(4) This Medication is NOT medically necessary for the following condition(s)

PHP Medi-Cal

lurbinectedin (Zepzelca®)

Coverage for a Non-FDA approved indication, requires that criteria outlined in Health and Safety Code § 1367.21, including objective evidence of efficacy and safety are met for the proposed indication.

Please refer to the Provider Manual and User Guide for more information.

(5) Additional Information

How supplied:

- 4 mg lyophilized powder in a single-dose vial

(6) References

- AHFS®. Available by subscription at <http://www.lexi.com>
- DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
- National Comprehensive Cancer Network Drug and Biologics Compendium (Version 2023). Available at: www.nccn.org.
- National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 3.2023). Available at: www.nccn.org.
- Zepzelca® (lurbinectedin) [Prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; 4/2022.

(7) Policy Update

Date of last review: 3Q2023

Date of next review: 3Q2024

Changes from previous policy version:

- No clinical change to policy following routine annual review.

*BSC Drug Coverage Criteria to Determine Medical Necessity
Reviewed by P&T Committee*